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THE LONG-RANGE CYTOTOXIC EFFECT IN TUMOR-BEARING ANIMALS
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R.E. Kavetsky Institute of Experimental Pathology, Oncology and Radiobiology, National Academy 
of Sciences of Ukraine, Kyiv 03022, Ukraine
Aim: The relationship between cancer and patient health is still of great interest for experimental and clinical oncology. The tumor can 
adversely affect surrounding and distant tissues as well. However, effects of the tumor on distant tissues are much less studied than its 
effects on surrounding tissues. This study was aimed to test whether the tumor could trigger cytotoxic and/or genotoxic signals with 
respect to the distant proliferative tissue such as bone marrow. Materials and Methods: Rats were subcutaneously implanted with 
Guerin carcinoma cells, and on the 12th and 18th days after implantation both cytotoxic and genotoxic effects were assessed by flow 
cytometry in acridine orange stained unfractionated bone marrow cells isolated from femur. The cytotoxic effect was assessed using 
ratios of the following cell populations: total nucleated cells (TNC)/total enucleated erythrocytes (TE); polychromatic erythrocytes 
(PCE)/normochromatic erythrocytes (NCE). The genotoxic effect was assessed by quantification of micronucleated PCE (MNPCE) 
within the population of PCE. Results: A significant cytotoxic effect was observed in tumor-bearing animals on the 12th and 18th days 
after implantation (≈ 2-fold decrease in both TNC/TE and PCE/NCE ratios compared with corresponding parameters in control 
animals). There was also a genotoxic effect in these animals (a slight increase in the number of MNPCE), however, this effect was 
insignificant. The PCE/NCE ratio reversely correlated with the tumor weight which is suggestive of the link between erythropoietic 
cytotoxicity and tumor progression. Conclusion: Cytotoxic insult to the bone marrow is likely to be associated with the mechanism(s) 
triggered by distantly located tumors whose growth may correlate with the cytotoxic effect.
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The tumor-host interaction is a complex process 
that puzzles experimental and clinical oncologists for 
decades. The problem of interaction of the tumor with 
the host was well summarized by Kavetsky in 1977 [1]. 
Even though at present time new and more accurate 
techniques are being used in cancer research, much 
work is yet to be done to wider uncover this problem. 
It is not surprising that a large body of work has been 
focused on the study of effects of a tumor on sur-
rounding (adjacent) tissues and vice versa, a model 
which is attractive for several reasons: it is conve-
nient in terms of experimental design planning, and 
it is informative and precise in terms of visualization 
of effects and dissection of mechanisms. Tumor 
cells by interacting with its stroma have been found 
to change their phenotype and biological properties 
[2, 3]. On the other hand, tumors have been shown 
to affect surrounding noncancerous cells causing 
DNA damage [4−6]. As for adverse effects of tumors 
on distant tissues, there is the only known fact that they 
can induce a complex DNA damage (double strand 
breaks (DSBs) and oxidatively induced clustered DNA 
lesions (OCDLs)), particularly in proliferative tissues 
(skin and crypts in the gastrointestinal organs) [7]. 
Since a proliferative tissue contains a large fraction 
of S-phase cells sensitive to DNA DSB formation 
(as evidenced by phosphorylation of histone H2AX [8, 
9]), proliferation of cells in this tissue exposed to DNA 
damaging agents could be delayed due to DNA repair 
processes. Cytotoxic/genotoxic insults frequently im-
pair the proliferating and maturational abilities of cells.
To test whether such a highly proliferative hema-
topoietic tissue as bone marrow is among sensitive 
targets for distantly located tumors, adult male rats 
were subcutaneously implanted with Guerin carcinoma 
(GC; uterine adenocarcinoma of rats) cells, and then 
on the 12th and 18th days after implantation cytotoxic 
and genotoxic effects were assessed in hematopoietic 
cells of unfractionated bone marrow according to the 
techniques proposed by Criswell et al. [10, 11]. In brief, 
the cytotoxic effect was assessed by flow cytomety 
using two parameters: 1) ratio of the population of to-
tal nucleated cells (TNC) to the population of total 
enucleated erythrocytes (TE) composed of immature 
polychromatic (PCE) and mature normochromatic 
erythrocytes (NCE); 2) ratio of the population of PCE 
to the population of NCE [10]. The TNC/TE ratio is used 
to determine overall myelosuppression, while the 
PCE/NCE ratio is used to specifically determine sup-
pression of erythropoiesis. Clastogenic agents that 
target the process of DNA replication are known to sup-
press cell proliferation thus causing decreases of these 
ratios [10, 12, 13]. TNC/TE and PCE/NCE ratios are 
key components of cytotoxicity assessment, among 
which the PCE/NCE ratio is most frequently used with 
the micronucleus (MN) test. The genotoxic effect was 
assessed by flow cytometric counting of micronucle-
ated PCE (MNPCE) within the population of PCE [11]. 
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MATERIALS AND METHODS
Animal tumor model. Adult random-bred male rats 
(250−300 g) were obtained from the vivarium of R.E. Ka-
vetsky Institute of Experimental Pathology, Oncology 
and Radiobiology, NAS of Ukraine (Kyiv, Ukraine). 
Guerin carcinoma (GC, or T8) cells were obtained from 
the Bank of Cell Lines from Human and Animal Tissues 
of the aforementioned Institute. Up to 90% of rats can 
be successfully implanted with this type of cells regard-
less of the strain of animals used for implantation [14]. 
The work with animals was performed according to the 
rules of local Ethic Committee. Tumors were implanted 
by subcutaneous injection (dorsally into the left flank) 
of 2.2 × 106 GC cells suspended in 0.5 ml of sterile 
physiological solution. On the 12th and 18th days after 
implantation animals were sacrificed. Tumors attached 
to the inner side of the skin were carefully removed 
with scissors and then weighed. Although this animal 
tumor model may be not highly syngeneic, this is not 
likely to be an issue, since the goal of our work was not 
investigation of a specific mechanism of the tumor-host 
interaction or anti-cancer drug delivery.  
Bone marrow isolation. Femur removal and 
bone marrow isolation procedures were performed 
as proposed [10]. Bone marrow cells were thoroughly 
flushed from the femur with 3 ml of FBS and kept at 
+4−6 °C before use.
Specimen processing and fixation. Bone mar-
row samples were kept in a fridge no longer than 
1.5 h before they were resuspended by vortexing and 
centrifuged at 300 × g for 5 min. In general, specimen 
processing and fixation procedures were performed 
as proposed [10]. The supernatant was discarded 
followed by washing cells in 5 ml of PBS. After cen-
trifugation them at 300 × g for 5 min, the supernatant 
was discarded and then the pellet was resuspended 
in 2 ml of PBS by vortexing. Cell aggregates were 
dissociated by gentle syringing of the suspension 
through a 21-gauge needle. While vigorous vortexing, 
0.2 ml of processed whole bone marrow was added 
to 5 ml of fixative solution: 1% glutaraldehyde (v/v) 
in PBS with 30 μg/ml of SDS (Merck, Germany). In this 
solution, erythrocytes become spherical [15]. Cells 
were fixed for 5 min and then centrifuged for an addi-
tional 5 min at 300 × g. The supernatant was removed 
followed by resuspension of cells in 0.5 ml of PBS. 
Fluorescence staining. This procedure was 
performed in accordance with the published protocol 
[11]. Solution A was prepared by dissolving in 100 ml 
(final volume) of distilled H2O of the following com-
ponents: 0.1 ml Triton X-100 (Loba Chemie, Austria), 
8 ml 1.0 N HCl, and 0.877 g NaCl. Solution B was 
prepared by mixing of 37 ml 0.1 M anhydrous citric 
acid with 63 ml 0.2 M Na2HPO4 (pH 6.0) and adding 
0.877 g NaCl, 34 mg EDTA disodium salt (Sigma, USA) 
and 0.6 ml of acridine orange (AO; Sigma) stock solution 
(1 mg/ml). Fixed cells (0.2 ml of cell suspension) were 
mixed with ice-cold Solutions A and B (0.4 and 1.2 ml, 
respectively) in a 12 × 75 mm centrifuge tubes. While 
shaking, cells were stained on ice for 30 min in the dark. 
They were then centrifuged at 300 × g for 5 min. After 
the supernatant was carefully removed, 1 ml of PBS 
was added to resuspend the pellet. Before flow cytom-
etry, the cell suspension was gently syringed through 
a 21-gauge needle to mainly analyze single cells. 
Flow cytometry.  Samples were analyzed 
on an EPICS XL flow cytometer (Beckman Coulter, 
USA) equipped with a 15 mW argon-ion laser (488 nm). 
Instrument settings were in general the same as recom-
mended [10, 11]. The forward light scatter (related to cell 
size) and the side light scatter (related to intracellular 
granularity) signals were collected in linear mode. The 
fluorescence of DNA- and RNA-bound AO was mea-
sured in the green fluorescence channel (FL1) through 
a 525/10-nm band-pass filter with logarithmic amplifica-
tion and in the far red fluorescence channel (FL4) through 
a 675/10-nm band-pass filter with logarithmic amplifica-
tion, respectively. An acquisition rate was ≈1000 cells per 
second. At least 1.5 × 105 events were collected for each 
sample. Analysis of the data was performed with the 
publicly available software “WinMDI” developed by Dr. 
J. Trotter (http://facs.scripps.edu/software.html). 
Cells were gated on forward scatter versus side scatter 
histograms to eliminate debris and aggregates from 
analysis, although microscopical observation showed 
that their numbers were very low. On the Forward scat-
ter versus FL1-Height histogram, events that represent 
populations of TNC, PCE, and NCE were compartmental-
ized well enough to perform analysis (Fig. 1). Although 
Criswell et al. [10] proposed to use the FL4- versus FL1-
Height histogram for quantification of TNC, PCE, and 
NCE, the Forward scatter versus FL1-Height histogram 
(presented in Fig. 1) can also be used for this purpose 
(both histograms gave similar apportionments of these 
cells). For cytotoxicity assessment, TNC/TE (where TE 
= PCE + NCE) and PCE/NCE ratios were used [10]. For 
genotoxicity assessment, MNPCE (shown by the arrow; 
Fig. 1) were defined within the population of PCE (shown 
in the region R2; Fig. 1), and then their number was calcu-
lated per 1000 PCE [11]. Since levels of micronucleated 
NCE usually correlate with levels of MNPCE, they were 
not analyzed.
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Fig. 1. Forward scatter versus FL1-Height contour plot of AO-
stained unfractionated bone marrow cells that were isolated from 
the femur of control (intact) rat. The apportionment of TNC (in the re-
gion R1), PCE (in the region R2), and NCE (in the region R3) is 83.1, 
10.8, and 6.1%, respectively. Therefore, ratios PCE/NCE and TNC/
TE (where TE = PCE + NCE) are 1.8 and 4.9, respectively. The arrow 
shows the location of MNPCE whose frequency is 4.5/1000 PCE
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Statistical analysis. The statistical significance 
of differences between mean values was assessed 
by the Student’s t-test. Values P < 0.05 were conside-
red as statistically significant.
RESULTS
In the bone marrow isolated from femurs of GC-
bearing rats on the 12th and 18th days post-implantation 
there was about a 2-fold drop in both TNC/TE and 
PCE/NCE ratios compared to corresponding controls 
(P < 0.05; Fig. 2). These ratios were not sufficiently 
changed with the time post-implantation (P > 0.05; 
Fig. 2). Levels of MNPCE in the bone marrow of GC-
bearing rats on the 12th and 18th days post-implantation 
were slightly higher than the level of MNPCE in the 
bone marrow of the control group of animals (increas-
ing trend), although these elevations were insignificant 
(P > 0.05; Fig. 3).
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Fig. 2. TNC/TE and PCE/NCE ratios obtained from flow cytomet-
ric analysis of AO-stained bone marrow cells that were isolated 
from femurs of control rats (denoted as CTR) and GC-bearing 
rats on the 12th and 18th days post-implantation (denoted as GC 
(12 days) and GC (18 days), respectively). Data shown are the 
mean ± standard error of the mean
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Fig. 3. Frequencies of MNPCE obtained from flow cytometric 
analysis of AO-stained bone marrow cells that were isolated 
from femurs of control rats (denoted as CTR) and GC-bearing 
rats on the 12th and 18th days post-implantation (denoted as GC 
(12 days) and GC (18 days), respectively). Data shown are the 
mean ± standard error of the mean
To assess whether the cytotoxic effect depends 
upon the tumor progression, we generated the 
scatter plot of tumor masses and corresponding 
PCE/NCE ratios (Fig. 4). This plot shows that in the 
majority of GC-bearing animals the PCE/NCE ratio 
reversely correlated with the tumor mass. However, 
the slope of the regression line depended upon the 
time passed since implantation of tumor cells. For 
the data collected from animals that carried tumors 
for up to 18 days, compared with the data collected 
from animals that carried tumors for up to 12 days, 
the slope of the regression line was markedly steeper 
(Fig.4). Unlike the plot of PCE/NCE ratios versus tu-
mor masses, the plot of TNC/TE ratios versus tumor 
masses showed a much sparser distribution of the data 
points whose regression lines were strictly horizontal, 
which is indicative of lack of correlation between these 
two parameters (data not shown). On the 12th and 18th 
days post-implantation the tumor mass values were 
5.2 ± 0.6 and 6.4 ± 2.0 g, respectively (data shown are 
the mean ± standard error of the mean).
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Fig. 4. Scatter plot generated from data points of tumor mass 
values and corresponding PCE/NCE ratio values. Distributions 
of data points acquired from GC-bearing rats on the 12th and 18th 
days post-implantation are shown by closed boxes (grey) and 
open boxes (white), respectively
DISCUSSION
A significant decrease in both TNC/TE and PCE/
NCE ratios is indicative of serious cytotoxic insult 
to the bone marrow of GC-bearing rats. This insult 
is likely to affect a large number of cells residing in the 
bone marrow as evidenced by ≈2-fold decrease in the 
TNC/TE ratio (Fig. 2). Cytotoxic effects in tissues 
distant to sites of implanted tumors have not been 
previously reported. As for genotoxicity in the bone 
marrow of GC-bearing rats, this effect, perhaps, ex-
ists to some extent (a slight elevation in the number 
of MNPCE; Fig. 3). More studies with a larger cohort 
of animals are probably needed to fully uncover this 
issue. At first it might seem that cytotoxicity in the 
bone marrow of GC-bearing animals does not depend 
on tumor growth (e.g., there was no further decrease 
in TNC/TE or PCE/NCE ratios, and there was no further 
increase in the level of MNPCE, if the data collected 
from rats that carried tumors for up to 18 days are 
compared with the data collected from rats that carried 
tumors for up to 12 days; Fig. 2). Nevertheless, cor-
relation analysis of tumor masses and corresponding 
PCE/NCE ratios did reveal tumor growth dependent 
cytotoxicity in the bone marrow, namely erythropoietic 
cytotoxicity (Fig. 4). Perhaps, erythropoietic cells are 
more susceptible to tumor-associated cytotoxic stress 
than cells of other lineages. Impaired erythropoiesis 
is known to frequently accompany cancer-related ane-
mia [16]. Inflammatory cytokines, whose production 
is induced by cancer, suppress erythroid progenitor 
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cell proliferation and erythropoietin production as well 
[17]. Thus, the PCE/NCE ratio appears to be a valu-
able parameter to monitor progression/regression 
of tumors that are capable of affecting erythropoiesis.
Since cytotoxicity is often accompanied by DNA le-
sions, we cannot exclude the possibility of DNA damage 
in the bone marrow of rats implanted with GC. If a com-
plex DNA damage occurs, its repair can be delayed thus 
causing suppressed cell proliferation, which is one of the 
cytotoxicity manifestations. An insignificant genotoxic 
effect observed in this study (a slight elevation in the 
number of MNPCE; Fig. 3), perhaps, supports an as-
sumption that DNA damage may occur in the bone mar-
row of rats implanted with GC. Redon et al. [7] in their re-
cent study on mice that were subcutaneously implanted 
with tumors, such as B16 melanoma, M5076 sarcoma, 
and COLON26 carcinoma, have reported the induction 
of complex DNA damage (DSBs and OCDLs) in distant 
proliferative tissues, particularly in skin and crypts 
of gastrointestinal organs. Similar DNA lesions could 
be in our study. However, the most intriguing issue 
in this “tumor-induced bystander effect” is mechanism 
of its induction. Tumor-associated macrophages, major 
players of cancer-related inflammation [18], have been 
found in aforementioned mouse tumors, and also, in-
creased amounts of activated macrophages have been 
found in gastrointestinal tissues and skin [7]. Moreover, 
cytokine CCL2 (also known as monocyte chemoat-
tractant protein-1), which is linked to chronic inflam-
mation conditions and cancer [19], has been shown 
as an essential mediator in tumor-induced DNA damage 
in distant tissues [7]. This cytokine has been reported 
to be secreted by tumor cells, normal tissues, and im-
mune cells [20]. However, in the study by Redon et al. 
[7], CCL2 is unlikely to be produced by the tumor cells 
themselves, since tumor-bearing CCL2-deficient mice, 
compared with tumor-bearing CCL2-proficient mice, 
showed neither the presence of this cytokine in the 
serum nor elevation of DNA damage (DSBs or OCDLs) 
in distant tissues [7]. To induce DNA damage in a distant 
tissue, tumor cells have to activate resident or distant 
immune cells that after being activated release geno-
toxic substances including ROS. Tumor cells are likely 
to activate immune cells via direct and indirect contacts 
as well [7], since tumor cells are capable of secreting 
a variety of cytokines and other factors [21].
The fact that a tumor together with expressed 
CCL2 is an inevitable prerequisite to induce in distant tis-
sues DNA lesions (whose level correlates with prolifera-
tive state of the tissue) may also take place in our study. 
Tumor growth dependent erythropoietic cytotoxicity 
in GC-bearing rats is likely to be a part of the common 
mechanism of tumor-induced inflammatory response.
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